OSTX Positive Sentiment
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
Key Takeaway: OS Therapies has been granted meetings with the U.S. FDA, U.K. MHRA, EMA, and the Australian Therapeutic Goods Administration. These meetings are to discuss the global confirmatory Phase 3 trial for OST-HER2, aimed at treating metastatic osteosarcoma. This development marks a significant step forward in the company's clinical efforts.
Price reaction · baseline $1.37 (2026-03-26 close) · hit pre-market · clean, no other OSTX news in the window
day 0 close · peak
+2.9%
Market Sentiment Analysis
POSITIVE FACTORS
- OS Therapies has secured meetings with multiple regulatory agencies.
- The global confirmatory Phase 3 trial for OST-HER2 is progressing.
- Engagement with the FDA, MHRA, EMA, and TGA indicates strong interest.